This is comparable to the ORR of second-line docetaxel in metastatic NSCLC (albeit with much less toxicity) and is lower than second-line PD-1/PD-L1 immunotherapy in the same, unselected population (8–11). Here, PDCD1 is linked to non-small cell lung carcinoma.